2-(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazol-3'-yl)ethanol | 765900-69-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazol-3'-yl)ethanol
• 英文别名: 2-(4-methyl-6-(1-methyl-1H-benzo[d]imidazol-2-yl)-2-propyl-1H-benzo[d]imidazol-1-yl)ethanol；2-[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]ethanol
• CAS: 765900-69-4
• 化学式: C₂₁H₂₄N₄O
• 分子量: 348.448
• InChiKey: AHMMDADZPHLOQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazol-3'-yl)ethanol 、 甲基磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以75%的产率得到2-(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazol-3'-yl)ethyl methanesulfonate
  参考文献：
  名称：

  Design, Synthesis, and Docking Studies of Novel Benzimidazoles for the Treatment of Metabolic Syndrome

  摘要：

  In addition to lowering blood pressure, telmisartan, an angiotensin (AT,) receptor blocker, has recently been shown to exert pleiotropic effects as a partial agonist of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma). On the basis of these findings and docking pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of benzimidazole derivatives were designed and synthesized as dual PPAR gamma agonist/angiotensin II antagonists for the possible treatment of metabolic syndrome. Compound 4, a bisbenzimidazole derivative showed the best affinity for the AT, receptor with a K-i = 13.4 nM, but it was devoid of PPAR gamma activity. On the other hand 9, a monobenzimidazole derivative, showed the highest activity in PPAR gamma transactivation assay (69% activation) with no affinity for the AT(1) receptor. Docking studies lead to the designing of a molecule with dual activity, 10, with moderate PPAR gamma activity (29%) and affinity for the AT(1) receptor (K-i = 2.5 mu M).

  DOI：

  10.1021/jm901272d
• 作为产物：
  描述：

  ethyl 2-(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazol-3'-yl)acetate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以88%的产率得到2-(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazol-3'-yl)ethanol
  参考文献：
  名称：

  Design, Synthesis, and Docking Studies of Novel Benzimidazoles for the Treatment of Metabolic Syndrome

  摘要：

  In addition to lowering blood pressure, telmisartan, an angiotensin (AT,) receptor blocker, has recently been shown to exert pleiotropic effects as a partial agonist of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma). On the basis of these findings and docking pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of benzimidazole derivatives were designed and synthesized as dual PPAR gamma agonist/angiotensin II antagonists for the possible treatment of metabolic syndrome. Compound 4, a bisbenzimidazole derivative showed the best affinity for the AT, receptor with a K-i = 13.4 nM, but it was devoid of PPAR gamma activity. On the other hand 9, a monobenzimidazole derivative, showed the highest activity in PPAR gamma transactivation assay (69% activation) with no affinity for the AT(1) receptor. Docking studies lead to the designing of a molecule with dual activity, 10, with moderate PPAR gamma activity (29%) and affinity for the AT(1) receptor (K-i = 2.5 mu M).

  DOI：

  10.1021/jm901272d

文献信息

• Novel PPAR agonists, pharmaceutical compositions and uses thereof
  申请人：Pershadsingh A. Harrihar

  公开号：US20050020654A1

  公开（公告）日：2005-01-27

  The present invention provides novel compounds and pharmaceutical compositions thereof, which at least partially activate PPARγ and may further inhibit the activity of the AT1 receptor. The novel compounds include certain substituted benzimidazole compounds of Formulae I and II, infra. The invention also provides methods of treating inflammatory and metabolic disorders and methods for screening compounds for the capability to treat or prevent an inflammatory or metabolic disorder.

  本发明提供了新型化合物及其药物组合物，它们至少部分激活PPARγ，并可能进一步抑制AT1受体的活性。这些新型化合物包括下式I和II的某些取代苯并咪唑化合物。本发明还提供了治疗炎症和代谢性疾病的方法，以及筛选化合物以治疗或预防炎症或代谢性疾病的能力的方法。
• [EN] NOVEL PPAR AGONISTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] NOUVEAUX AGONISTES PPAR, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BETHESDA PHARMACEUTICALS INC

  公开号：WO2004082621A2

  公开（公告）日：2004-09-30

  The present invention provides novel compounds and pharmaceutical compositions thereof, which at least partially activate PPARϜ and may further inhibit the activity of the AT1 receptor. The novel compounds include certain substituted benzimidazole compounds of Formulae I and II, infra. The invention also provides methods of treating inflammatory and metabolic disorders and methods for screening compounds for the capability to treat or prevent an inflammatory or metabolic disorder.
• Design, Synthesis, and Docking Studies of Novel Benzimidazoles for the Treatment of Metabolic Syndrome
  作者：Cassia S. Mizuno、Amar G. Chittiboyina、Falgun H. Shah、Akshay Patny、Theodore W. Kurtz、Harrihar A. Pershadsingh、Robert C. Speth、Vardan T. Karamyan、Paulo B. Carvalho、Mitchell A. Avery

  DOI：10.1021/jm901272d

  日期：2010.2.11

  In addition to lowering blood pressure, telmisartan, an angiotensin (AT,) receptor blocker, has recently been shown to exert pleiotropic effects as a partial agonist of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma). On the basis of these findings and docking pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of benzimidazole derivatives were designed and synthesized as dual PPAR gamma agonist/angiotensin II antagonists for the possible treatment of metabolic syndrome. Compound 4, a bisbenzimidazole derivative showed the best affinity for the AT, receptor with a K-i = 13.4 nM, but it was devoid of PPAR gamma activity. On the other hand 9, a monobenzimidazole derivative, showed the highest activity in PPAR gamma transactivation assay (69% activation) with no affinity for the AT(1) receptor. Docking studies lead to the designing of a molecule with dual activity, 10, with moderate PPAR gamma activity (29%) and affinity for the AT(1) receptor (K-i = 2.5 mu M).